Drugs

, Volume 55, Issue 1, pp 145–163 | Cite as

Topical Mometasone

A Review of its Pharmacological Properties and Therapeutic Use in the Treatment of Dermatological Disorders
Adis Drug Evaluation

Summary

Synopsis

Mometasone, a synthetic 16α-methyl analogue of beclomethasone, is classified as a ‘potent’ glucocorticoid for dermatological use. It is available as 0.1% cream, ointment and lotion formulations for the treatment of patients with inflammatory glucocorticoid-responsive dermatoses.

In patients with atopic dermatitis, the effects of mometasone 0.1% applied once daily over 2 to 3 weeks were similar to those of other glucocorticoids of similar potency, such as betamethasone dipropionate 0.05% twice daily and methylprednisolone aceponate 0.1% once daily. Mometasone 0.1% was significantly superior to twice-daily application of less potent glucocorticoids such as clobetasone 0.05%, hydrocortisone 1.0%, hydrocortisone butyrate and hydrocortisone valerate 0.2%. In patients with seborrhoeic dermatitis, mometasone 0.1% was more effective than ketoconazole 2.0% and hydrocortisone 1.0% in trials lasting 4 or 6 weeks. In the management of scalp psoriasis and psoriasis vulgaris, mometasone 0.1% applied once daily for 2 to 8 weeks was generally more effective than other glucocorticoids of similar or weaker potency such as betamethasone valerate 0.1%, fluocinolone acetonide 0.025%, fluticasone propionate 0.005%, triamcinolone acetonide 0.1% and hydrocortisone 1.0% and as effective as diflucortolone valerate 0.1%. Alternate day application of mometasone 0.1% for 2 weeks was as effective as once-daily application in maintaining symptom control in a small number of patients with psoriasis vulgaris.

Although mometasone demonstrates greater anti-inflammatory activity and a longer duration of action than betamethasone, it has low potential to cause adverse systemic effects such as suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Moreover, its atrophogenic potential is low and no greater than that of other glucocorticoids in its class, such as betamethasone valerate. Transient, mild to moderate, local adverse effects such as burning, stinging, folliculitis, dryness, acneiform eruptions and signs of skin atrophy have been reported with mometasone. Mometasone has shown a low risk of primary sensitisation and cross-reactions in preliminary patch test studies.

Mometasone is a well tolerated topical glucocorticoid effective in the management of patients with atopic dermatitis, seborrhoeic dermatitis, scalp psoriasis and psoriasis vulgaris. In addition to its low potential for causing primary sensitisation and cross-reactions with other topical glucocorticoids, mometasone offers the convenience of once-daily administration.

Pharmacological Properties

Mometasone has high lipophilicity and displays greater in vitro affinity for glucocorticoid receptors in rat epidermis than betamethasone dipropionate. In suppressing erythema induced by ultraviolet (UV)-B light, mometasone showed greater activity and a longer duration of action than betamethasone dipropionate and betamethasone valerate. However, it showed little potential to suppress the hypothalamic-pituitary-adrenal axis in patients and healthy volunteers.

An in vitro study on human fibroblasts and keratinocytes reported the anti-proliferative effects of mometasone to be negligible or small compared with those of betamethasone valerate. No clinical or histological signs of skin atrophy were observed in 6 volunteers after 12 months of once-daily application of mometasone 0.1% cream. Some clinical trials have found the atrophogenic potential of mometasone to be low and similar to that of hydrocortisone, prednicarbate, betamethasone valerate and methylprednisolone aceponate. However, in one trial, mometasone 0.1% ointment was associated with a significantly greater incidence and severity of skin atrophy and telangiectasia than methylprednisolone aceponate 0.1% ointment.

Little topically applied mometasone reaches the systemic circulation. In human volunteers, only 0.7% of mometasone 0.1% ointment was systemically absorbed after a contact time of 8 hours without occlusive dressing. After application of 10g 0.1% ointment under occlusion, the plasma concentration of mometasone peaked at about 130 ng/L in 12 hours and then declined rapidly.

Therapeutic Use

Atopic dermatitis. In short term studies (≤6 weeks) once-daily mometasone 0.1% cream or ointment was significantly more effective in reducing total sign and symptom severity scores than twice-daily clobetasone 0.05% ointment, clobetasone 0.05% cream, hydrocortisone butyrate cream, hydrocortisone valerate 0.2% cream and hydrocortisone 1.0% cream and as effective as once-daily methylprednisolone aceponate 0.1% cream or twice-daily betamethasone dipropionate 0.05% ointment in the treatment of moderate to severe atopic dermatitis.

Seborrhoeic dermatitis. Once-daily application of mometasone 0.1% solution was more effective and showed a faster onset of action than ketoconazole 2.0% shampoo applied twice weekly over 4 weeks in the treatment of patients with moderate to severe seborrhoeic dermatitis. Significantly greater improvement was observed after 6 weeks with mometasone 0.1% cream applied once daily than with hydrocortisone 1.0% cream applied twice daily. Psoriasis. Mometasone 0.1% lotion or ointment applied once daily was significantly more effective than twice-daily betamethasone valerate 0.1% lotion or ointment over 2 to 8 weeks in 3 trials in patients with scalp psoriasis or psoriasis vulgaris. The once-daily application of mometasone 0.1% cream, lotion or ointment formulations produced significantly greater reductions in total psoriatic symptom scores than once-daily hydrocortisone 1% ointment, twice-daily fluticasone propionate 0.005% ointment, triamcinolone acetonide 0.1% lotion or ointment or 3-times-daily fluocinolone acetonide 0.025% cream or ointment. In patients with psoriasis vulgaris, mometasone applied once daily was as effective as twice-daily diflucortolone valerate 0.1% ointment and triamcinolone acetonide 0.1% cream. Results of a preliminary short term study suggest that application of mometasone 0.1% ointment on alternate days may be as effective as once-daily application in maintenance therapy in patients with psoriasis vulgaris.

Tolerability

Topical mometasone 0.1% cream was associated with local cutaneous adverse effects in 1.6 and 7.0% of 319 adult and 74 paediatric patients, respectively. The most commonly encountered adverse effects included stinging, burning, pruritus, folliculitis, dryness, acneiform/erythematous eruptions, tenderness and signs of skin atrophy. These adverse effects were transient and of mild or mild to moderate intensity.

Preliminary patch test studies have reported that the risk of primary sensitisation or cross-reaction with mometasone is low, even in patients known to be hypersensitive to glucocorticoids.

Dosage and Administration

Mometasone 0.1% cream, ointment or lotion is indicated for the symptomatic relief of inflammation and pruritus in patients with glucocorticoid-responsive dermatoses. It should be applied without occlusion to the affected areas once daily. Like other topical glucocorticoids, mometasone should not be used in patients with primary cutaneous viral, bacterial or fungal infections, rosacea, acne, perioral dermatitis, or perianal or genital pruritus. It may be used with caution in children aged ≥2 years.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mori M, Pimpinelli N, Giannotti B. Topical corticosteroids and unwanted local effects: Improving the benefit/risk ratio. Drug Saf 1994; 10(5): 406–12PubMedCrossRefGoogle Scholar
  2. 2.
    Ponec M. Glucocorticoids and cultured human skin cells: specific intracellular binding and structure-activity relationships. Br J Dermatol 1982; 107 Suppl. 23: 24–9PubMedCrossRefGoogle Scholar
  3. 3.
    Shapiro EL, Gentles MJ, Tiberi RL, et al. 17-Heteroaryl esters of corticosteroids. 2.11 beta-hydroxy series. J Med Chem 1987; 30: 1581–8PubMedCrossRefGoogle Scholar
  4. 4.
    Popper TL, Gentles MJ, Kung TT, et al. Structure-activity relationships of aseries of novel topical corticosteroids. J Steroid Biochem Mol Biol 1987; 27(4–6): 837–43Google Scholar
  5. 5.
    Di Nardo A, Giusti G, Mantovani L, et al. Inhibition of elicitation of contact dermatitis in humans by mometasone furoate: evaluation by means of 20-MHz B scanning associated with image analysis. Dermatology 1997; 195: 137–41PubMedCrossRefGoogle Scholar
  6. 6.
    Gustafsson JA, Carlstedt-Duke J, Stromstedt PE, et al. Structure, function and regulation of the glucocorticoid receptor. Prog Clin Biol Res 1990; 322: 889–95Google Scholar
  7. 7.
    Flower RJ, Rothwell NJ. Lipocortin-lxellular mechanisms and clinical relevance. Trends Pharmacol Sci 1994; 15: 65–80CrossRefGoogle Scholar
  8. 8.
    Goulding NJ, Guyre PM. Glucocorticoids, lipocortins and the immune system. Curr Opin Immunol 1993; 5: 108–13PubMedCrossRefGoogle Scholar
  9. 9.
    Goulding NJ, Guyre PM. Regulation of inflammation by lipocortin-1. Immunol Today 1992; 13: 295–7PubMedCrossRefGoogle Scholar
  10. 10.
    Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of IκB in mediation of immunosuppression by glucocorticosteroids. Science 1995; 270: 283–6PubMedCrossRefGoogle Scholar
  11. 11.
    Auphan N, Didonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 270: 286–90PubMedCrossRefGoogle Scholar
  12. 12.
    Srivastava D, Thompson EB. Two glucocorticoid binding sites on the human glucocorticoid receptor. Endocrinology 1990; 127: 1770–8PubMedCrossRefGoogle Scholar
  13. 13.
    Do YS, Loose DS, Feldman D. Heterogeneity of glucocorticoid binders: a unique and classical dexamethasone-binding site in bovine tissues. Endocrinology 1979; 105: 1055–63PubMedCrossRefGoogle Scholar
  14. 14.
    Bamberger CM, Bamberger A-M, de Castro M, et al. Glucocorticoid receptor β, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995; 95: 2435–41PubMedCrossRefGoogle Scholar
  15. 15.
    Smith K, Shuster S. Characterization and quantification of epidermal and dermal glucocorticoid receptors in the rat. J Invest Dermatol 1984; 82: 44–8PubMedCrossRefGoogle Scholar
  16. 16.
    Leiferman KM, Schroeter A, Kirschner MK, et al. Characterization of the glucocorticoid receptor in human skin. J Invest Dermatol 1983; 81: 355–61PubMedCrossRefGoogle Scholar
  17. 17.
    Smith K, Shuster S. Characterization of the glucocorticoid receptor in human epidermis and dermis. Clin Exp Dermatol 1987; 12: 83–8PubMedCrossRefGoogle Scholar
  18. 18.
    Isogai M, Shimizu H, Esumi Y, et al. Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol 1993 Feb; 44: 141–5PubMedCrossRefGoogle Scholar
  19. 19.
    Blackwell GJ, Carnuccio R, DiRosa M, et al. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature 1980 Sept 11; 287: 147–9PubMedCrossRefGoogle Scholar
  20. 20.
    Hammarström S, Hamburg M, Duell EA, et al. Glucocorticoid in inflammatory proliferative skin disease reduces arachidonic acid and hydroxyeicosatetraenoic acids. Science 1977 Sept 2; 197(4307): 994–6PubMedCrossRefGoogle Scholar
  21. 21.
    Crocker IC, Zhou C-Y, Kreutner W, et al. Glucocorticoids inhibit leukotriene release by mixed leukocytes [abstract]. J Allergy Clin Immunol 1996; 97(Pt 3): 289CrossRefGoogle Scholar
  22. 22.
    Umland SP, Nahrebne DK, Razac S, et al. Effects of mometasone furoate and other glucocorticoids on cytokine production from cultured peripheral blood CD4+ T cells [abstract]. J Allergy Clin Immunol 1996; 97(Pt 3): 288CrossRefGoogle Scholar
  23. 23.
    Barton BE, Jakway JP, Smith SR, et al. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol 1991; 13(3): 251–61PubMedCrossRefGoogle Scholar
  24. 24.
    Nissen JB, Kragballe K. Enkephalin levels in psoriatic skin after treatment with cacipotriol, mometasone furoate and heliobalneotherapy [abstract no. 349]. J Invest Dermatol 1997; 107: 462Google Scholar
  25. 25.
    Berti E, Richelda R, Bianchi B, et al. Evaluation of infiltrate cytokines receptors and adhesion molecules expression in psoriasis during topical treatment with mometasone furoate [abstract no. P-72]. In: American Academy of Dermatology: 1995 Annual Meeting Program supplement. New Orleans (LA), 1995Google Scholar
  26. 26.
    Bjerring P. Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans-inhibition of UV-B-induced inflammation monitored by laser doppler blood flowmetry. Skin Pharmacol 1993; 6(3): 187–92PubMedCrossRefGoogle Scholar
  27. 27.
    Kecskés A, Heger-Mahn D, Kuhlmann RK, et al. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal antiinflammatory activity. J Am Acad Dermatol 1993 Oct; 29: 576–80PubMedCrossRefGoogle Scholar
  28. 28.
    Brannan MD, Seiberling M, Cutler DL, et al. Lack of systemic activity with intranasal mometasone furoate [abstract]. J Allergy Clin Immunol 1996; 97(Pt 3): 198CrossRefGoogle Scholar
  29. 29.
    Brannan MD, Herron JM, Reidenberg P, et al. Lack of HPA axis suppression following 36 days of intranasal mometasone furoate [abstract]. 1996 Annual Meeting of the American College of Allergy, Asthma and Immunology: 1996: 76Google Scholar
  30. 30.
    Bressinck R, Williams J, Peets E. Comparison of the effect of mometasone furoate ointment 0.1%, and hydrocortisone ointment 1%, on adrenocortical function in psoriasis patients. Today’S Ther Trends 1988; 5(4): 25–35Google Scholar
  31. 31.
    Visscher HW, Ebels JT, Roders GA, et al. Randomised crossover comparison of adrenal suppressive effects of dermal creams containing glucocorticosteroids. Eur J Clin Pharmacol 1995; 48(2): 123–5PubMedCrossRefGoogle Scholar
  32. 32.
    Higashi N, Katagiri K. Percutaneous absorption of 0.1% mometasone furoate ointment fate, excretion and adrenocortical suppression [in Japanese]. Skin Res 1990; 32(3): 395–402Google Scholar
  33. 33.
    Hadzija B W, Ambrose WW. Comparison of cosmetic and physicochemical properties of six topical corticosteroid creams. Cutis 1996 Feb; 57: 13–8PubMedGoogle Scholar
  34. 34.
    Hoybye A, Moller SB, De Cunha Bang F, et al. Continuous and intermittent treatment of atopic dermatitis in adults with mometasone furoate versus hydrocortisone 17-butyrate. Curr Ther Res 1991 Jul; 50: 67–72Google Scholar
  35. 35.
    Vernon HJ, Lane AT, Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol 1991 Apr; 24: 603–7PubMedCrossRefGoogle Scholar
  36. 36.
    Ishibashi Y, Harada S, Niimura M, et al. Long term topical application of 0.1% mometasone furoate ointment and cream. Studies on systemic effects, local adverse reactions and clinical effects [in Japanese] [English abstract]. Rinsho Iyaku 1990 Aug; 6: 1655–69Google Scholar
  37. 37.
    Kelly JW, Cains GD, Railings M, et al. Safety and efficacy of mometasone furoate cream in the treatment of steroid responsive dermatoses. Australas J Dermatol 1991; 32(2): 85–91PubMedCrossRefGoogle Scholar
  38. 38.
    Rafanelli A, Rafanelli S, Stanganelli I, et al. Mometasone furoate in the treatment of atopic dermatitis in children. J Eur Acad Dermatol Venereol 1993; 2(3): 225–30CrossRefGoogle Scholar
  39. 39.
    Homey B, Schuppe H-C, Assmann T, et al. A local lymph node assay to analyse the immunosuppressive effects of topically applied drugs. Eur J Pharmacol 1997 May 1; 325: 199–207PubMedCrossRefGoogle Scholar
  40. 40.
    Robertson DB, Maibach HI. Topical glucocorticoids. In: Schleimer RP, Claman HN, Oronsky A, editors. Anti-inflammatory steroid action. San Diego: Academic Press, 1989: 494–524Google Scholar
  41. 41.
    Cornell RC, Stoughton RB. The use of topical steroids in psoriasis. Dermatol Clin 1984; 2: 397–409Google Scholar
  42. 42.
    Stenmovic DU. Corticosteroid-induced atrophy of the skin with telangiectasia: a clinical and experimental study. Br J Dermatol 1972; 87: 548–56CrossRefGoogle Scholar
  43. 43.
    Hein R, Bosserhoff A, Wach F, et al. Effect of a newly synthesized glucocorticosteroid—mometasone furoate: on human keratinocytes and fibroblasts in vitro [abstract]. In: International Meeting Skin Therapy Update 94: 1994: 256Google Scholar
  44. 44.
    Kerscher MJ, Hart H, Korting HC, et al. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther 1995 Apr; 33: 187–9PubMedGoogle Scholar
  45. 45.
    Katz HI, Prawer SE, Watson MJ, et al. Mometasone furoate ointment 0.1% vs. hydrocortisone ointment 1.0% in psoriasis. Atrophogenic potential. Int J Dermatol 1989 Jun; 28: 342–4PubMedCrossRefGoogle Scholar
  46. 46.
    Brasch J. The atrophogenic potential of mometasone furoate in a clinical long-term study [in German] [English abstract]. Z Hautkr 1991; 66(9): 785–7Google Scholar
  47. 47.
    Koivukangas V, Karvonen J, Risteli J, et al. Topical mometasone furoate and betamethasone-17-valerate decrease collagen synthesis to a similar extent in human skin in vivo. Br J Dermatol 1995 Jan; 132: 66–8PubMedCrossRefGoogle Scholar
  48. 48.
    Hoffman K, Auer T, Stucker M, et al. Skin atrophy and vasoconstriction with mometasone furoate compared with methylprednisolone and hydrocortisone. Schering-Plough Corporation Limited, data on file, November, 1997Google Scholar
  49. 49.
    Schering Corporation. Product information. Kenilworth (NJ): Schering Corporation, 1995. (Data on file)Google Scholar
  50. 50.
    Wang C-J, Tian ZG, Byrnes K, et al. A competitive enzyme immunoassay for the direct determination of mometasone furoate (SCH-32088) in human plasma. J Pharm Biomed Anal 1992 Jul; 10: 473–9PubMedCrossRefGoogle Scholar
  51. 51.
    Lebwohl M, Lane AT, Berman B, et al. Efficacy and safety of 0.1% mometasone furoate cream versus 0.2% hydrocortisone valerate cream in pediatric patients with atopic dermatitis unresponsive to topical hydrocortisone treatment [abstract no. P-43]. Proceedings of the 55th Annual Meeting of the American Academy of Dermatology: 1997 Mar 21–26: San FranciscoGoogle Scholar
  52. 52.
    Bianchi B. Practical application of the SCORAD index in a clinical trial of children and adults with atopic dermatitis. Poster presentation in the 19th World Congress of Dermatology; 1997 Jun 15–20: SydneyGoogle Scholar
  53. 53.
    Giannetti A, Manzini BM, Bianchi B. Randomized, evaluation-blinded, multicenter study on onset of action, efficacy and safety of mometasone furoate 0.1% cream vs clobetasone butyrate 0.05% ointment in the treatment of atopic dermatitis [abstract no. P-229]. In: American Academy of Dermatology: 1995 Annual Meeting Program Supplement. New Orleans (LA), 1995Google Scholar
  54. 54.
    Marchesi E, Rozzoni M, Pini P, et al. Comparative study of mometasone furoate and betamethasone dipropionate in the treatment of atopic dermatitis. G Ital Dermatol Venereol 1994; 129(1–2): IX–XIIGoogle Scholar
  55. 55.
    Reidhav I, Svensson Å. Betamethasone valerate versus mometasone furoate cream once daily in atopic dermatitis. J Dermatol Treat 1996 Jun; 7: 87–8CrossRefGoogle Scholar
  56. 56.
    Hersle K, Mobacken H, Nordin P. Mometasone furoate solution 0.1% compared with ketoconazole shampoo 2% for seborrheic dermatitis of the scalp. Curr Ther Res Clin Exp 1996 Jul; 57: 516–22CrossRefGoogle Scholar
  57. 57.
    Medansky RS, Lepaw MI, Shavin JS, et al. Mometasone furoate cream 0.1% vs. hydrocortisone cream 1% in the treatment of seborrhoeic dermatitis. J Dermatol Treat 1992 Sep; 3: 125–8CrossRefGoogle Scholar
  58. 58.
    Swinehart JM, Barkoff JR, Dvorkin D, et al. Mometasone furoate lotion once daily versus triamcinolone acetonide lotion twice daily in psoriasis. Int J Dermatol 1989 Dec; 28: 680–1PubMedCrossRefGoogle Scholar
  59. 59.
    Vanderploeg DE, Cornell RC, Binder R, et al. Clinical trial in scalp psorisis. Mometasone furoate 0.1% applied once daily vs betamethasone valerate lotion 0.1% applied twice daily. Acta Ther 1989 Apr; 15: 145–52Google Scholar
  60. 60.
    Svensson Å, Reidhav I, Gisslén H, et al. A comparative study of mometasone furoate ointment and betamethasone valerate ointment in patients with psoriasis vulgaris. Curr Ther Res 1992 Sep; 52: 390–6CrossRefGoogle Scholar
  61. 61.
    Medansky RS, Bressinck R, Cole GW, et al. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent. Cutis 1988 Nov; 42: 480–5PubMedGoogle Scholar
  62. 62.
    Medansky RS, Brody NI, Kanof NB, et al. Clinical investigations of mometasone furoate—a novel nonfluorinated, topical corticosteroid. Semin Dermatol 1987; 6(2): 94–100Google Scholar
  63. 63.
    De Panfilis G, Braga D, Bianchi B. A randomised, multicentric, evaluator blinded study to compare mometasone furoate 0.1% ointment versus diflucortolone valerate 0.1% ointment in the treatment of psoriasis vulgaris [abstract no. P-111]. In: American Academy of Dermatology: 1995 Annual Meeting Program Supplement. New Orleans, LA, 1995Google Scholar
  64. 64.
    De Villez RL, Sher.AM, Breneman DL, et al. Comparison of the efficacy and safety of mometasone furoate ointment 0.1% once daily and fluticasone propionate ointment 0.005% twice daily in the management of psoriasis. Schering-Plough Corporation Limited, Kenilworth (NJ), 1997. (Data on file)Google Scholar
  65. 65.
    Santoro G, Fiallo P, Tagliapietra G, et al. Mometasone furoato a giorni alterni nel trattamento della psoriasi. G Ital Dermatol Venereol 1996; 131: 407–12Google Scholar
  66. 66.
    Lebwohl M, Peets E, Chen V. Limited application of mometasone furoate on the face and intertriginous areas: analysis of safety and efficacy. Int J Dermatol 1993 Nov; 32(11): 830–1PubMedCrossRefGoogle Scholar
  67. 67.
    Bianchi B. Mometasone furoate and methylprednisolone aceponate in patients with contact dermatitis. Poster presentation in the 19th World Congress of Dermatology, Sydney, Australia, Jun 15–20, 1997Google Scholar
  68. 68.
    Dominguez L, Hojyo T, Vega E, et al. Comparison of the safety and efficacy of mometasone furoate cream 0.1% and clobetasone butyrate cream 0.05% in the treatment of children with a variety of dermatoses. Curr Ther Res 1990 Jul; 48: 128–39Google Scholar
  69. 69.
    Gip L, Lindberg L, Nordin P, et al. Clinical study of mometasone furoate cream 0.1% compared to hydrocortisone butyrate cream 0.1% in treatment of atopic and seborrheic dermatitis. Today’s Ther Trends 1990; 8(3): 21–34Google Scholar
  70. 70.
    Viglioglia P, Jones ML, Peets EA. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses. J Int Med Res 1990 Nov–Dec; 18: 460–7PubMedGoogle Scholar
  71. 71.
    Wishart JM, Lee I-S. Mometasone versus betamethasone creams: a trial in dermatoses. N Z Med J 1993 May 26; 106: 203–5PubMedGoogle Scholar
  72. 72.
    Rajka G, Avrach W, Gärtner L, et al. Mometasone furoate 0.1% fatty cream once daily versus betamethasone valerate 0.1% cream twice daily in the treatment of patients with atopic and allergic contact dermatitis. Curr Ther Res 1993 Jul; 54: 23–9CrossRefGoogle Scholar
  73. 73.
    Dooms-Goossens A, Lepoittevin J-R Studies on the contact allergenic potential of momethasone furoate: a clinical and molecular study. Eur J Dermatol 1996 Jul–Aug; 6: 339–40Google Scholar
  74. 74.
    Wilkinson SM, Beck MH. Fluticasone propionate and mometasone furoate have a low risk of contact sensitization. Contact Dermatitis 1996 May; 34: 365–6PubMedCrossRefGoogle Scholar
  75. 75.
    Räsänen L, Tuomi M-L. Cross-sensitization to mometasone furoate in patients with corticosteroid contact allergy. Contact Dermatitis 1992 Nov; 27: 323–5PubMedCrossRefGoogle Scholar
  76. 76.
    Belsito DV. Allergic contact dermatitis to topical glucocorticosteroids. Cutis 1993; 52(5): 291–4PubMedGoogle Scholar
  77. 77.
    Lepoittevin JP, Drieghe J, Dooms-Goossens A. Studies in patients with corticosteroid contact allergy: understanding cross-reactivity among different corticosteroids. Arch Dermatol 1995; 131: 31–7PubMedCrossRefGoogle Scholar
  78. 78.
    Finlay AY. Quality-of-life issues and economic burden of psoriasis and atopic dermatitis: rationale for treatment. Clin Drug Invest 1995; 10 Suppl. 1: 1–6CrossRefGoogle Scholar
  79. 79.
    Taylor B, Wadsworth J, Wadsworth M, et al. Changes in the reported prevalence of childhood eczema since the 1939–45 war. Lancet 1984; II: 1255–7CrossRefGoogle Scholar
  80. 80.
    Hsieh KH, Tsai YT. Increasing prevalence of childhood allergic disease in Taipei,Taiwan, and the outcome. In: Miyamoto T, Okuda M, editors. Progress in allergy and clinical immunology. Gottingen: Hogrefe & Huber, 1992: 223–5Google Scholar
  81. 81.
    Hogan PA. Atopic dermatitis. Patient Manage N Z 1997 Apr; 26: 35–43Google Scholar
  82. 82.
    Lebwohl M, Abel E, Zanolli M, et al. Topical therapy for psoriasis. Int J Dermatol 1995; 34(10): 673–84PubMedGoogle Scholar
  83. 83.
    Dutz JP, Ho VC. Immunosuppressive agents in skin disorders:a comparative review. Clin Ther 1996; 5(4): 268–93Google Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations